100 results on '"Preskorn, Sheldon H."'
Search Results
2. Life-threatening Rash Due to Lamotrigine and a Failure to Understand Its Pharmacology: How Forensic Detective Work Uses Medical Knowledge and Clinical Pharmacology to Solve Cases.
3. Cerebral Anoxia in an 18-year-old Patient Being Treated for Major Depressive Disorder: How Forensic Detective Work Uses Medical Knowledge Including Clinical Pharmacology to Solve Cases.
4. How the Food and Drug Administration Drug Approval Process Relates to the Potential Approval of Intravenous Racemic Ketamine for Treatment-resistant Major Depression.
5. Personalized Medicine in the Treatment of a Patient With Obsessive-Compulsive Disorder With Clomipramine.
6. Eight Clinical Cases and the Lessons They Taught.
7. The Essential Parallels Between Clinical Practice and the Scientific Method.
8. Seven Mechanistically Different Classes of Medications Can Be Used to Treat Insomnia and Related Sleep Disorders.
9. Can the Publication of Case Series or Case Reports Lead to a Change in Clinical Practice?
10. Comparative Pharmacology of the 3 Marketed Dual Orexin Antagonists—Daridorexant, Lemborexant, and Suvorexant—Part 2. Principal Drug Metabolizing Enzyme, Drug-Drug Interactions, and Effects of Liver and Renal Impairment on Metabolism.
11. Building a Comprehensive Biopsychosocial Database to Identify Underlying Causes of Suicide and Improve Suicide Prevention.
12. Treatment of Agitation in Individuals With Bipolar Disorder or Schizophrenia: Lessons Learned for Clinical Psychiatry and Psychiatric Drug Development.
13. How an Understanding of the Function of the Locus Coeruleus Led to Use of Dexmedetomidine to Treat Agitation in Bipolar Disorder: Example of Rational Development of Psychiatric Medications.
14. Comparative Pharmacology of the 3 Marketed Dual Orexin Antagonists-Daridorexant, Lemborexant, and Suvorexant: Part 1: Pharmacokinetic Profiles.
15. Subtypes of Major Depressive Disorder Based on Pharmacological Responsiveness.
16. Fundamental Pharmacokinetic Concepts and Their Clinical Relevance: Clearance, Zero Versus First Order and Nonlinear Pharmacokinetics.
17. Charting and Handling Therapeutic Drug Monitoring Results: How they Differ From Most Laboratory Results.
18. Charting and Handling Genetic Test Results: How They Differ From Most Laboratory Results.
19. Consistency of the Antidepressant Effect of Intranasal Esketamine in Phase 3 Clinical Trials.
20. QTc, the Multitude of Ways It Is Calculated and Implications for Clinical Practice: A Case Example.
21. Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions?
22. COVID-19: Why Has the Mortality Rate Declined?
23. Two Clinically Important but Underutilized and Misunderstood Tools: Formulas to Estimate Creatinine Clearance and Therapeutic Drug Monitoring.
24. Mental Health Care Providers Dealing With Coronavirus Disease 2019 (COVID-19): What Is the Definition of a Case, How Is That Changing, and What Kinds of Tests Are Available?
25. The 5% of the Population at High Risk for Severe COVID-19 Infection Is Identifiable and Needs to Be Taken Into Account When Reopening the Economy.
26. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes.
27. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 8: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antidepressants.
28. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 7: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antipsychotics.
29. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 6: Pharmacodynamic Considerations.
30. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 5: Major Types of Pharmacodynamic DDIs Based on Mechanism of Action (With Updated Neuroscience-based Nomenclature).
31. Drug-drug Interactions in Psychiatric Practice, Part 4: Classification of Neuropsychiatric Medications Based on Their Principal Mechanisms of Action (With Updated Neuroscience-based Nomenclature).
32. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 3: Pharmacokinetic Considerations.
33. Knowledge of the Pharmacology of Antidepressants and Antipsychotics Yields Results Comparable With Pharmacogenetic Testing.
34. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 2: Strategies to Minimize Adverse Outcomes From Unintended DDIs.
35. Drug-drug Interactions in Psychiatric Practice, Part 1: Reasons, Importance, and Strategies to Avoid and Recognize Them.
36. CNS Drug Development, Lessons Learned, Part 5: How Preclinical and Human Safety Studies Inform the Approval and Subsequent Use of a New Drug-Suvorexant as an Example.
37. CNS Drug Development, Lessons Learned, Part 4: The Role of Brain Circuitry and Genes-Tasimelteon as an Example.
38. CNS Drug Development: Lessons Learned Part 3: Psychiatric and Central Nervous System Drugs Developed Over the Last Decade-Implications for the Field.
39. Switching From the Oral to the Depot Formulation of a Medication: Clinically Relevant Pharmacokinetic Concepts and Considerations.
40. Tardive Dyskinesia: A Historical Perspective.
41. Use of an Analog Scale in the Treatment of Patients With Bipolar Disorder to Optimize Assessment and Clinical Outcome.
42. Use of an Analog Scale in the Treatment of Patients With Major Depressive Disorder to Optimize Assessment and Clinical Outcome.
43. National Initiative to Prevent Suicide (NIPS): A New Proposal to Improve the Understanding and Prevention of Suicide.
44. New Laboratory Tests in Psychiatry: What Should Mental Health Practitioners Know?
45. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data.
46. An Individual With 2 Distinct Nonpathologic Identities.
47. A Way of Conceptualizing Benzodiazepines to Guide Clinical Use.
48. How Commonly Used Inclusion and Exclusion Criteria in Antidepressant Registration Trials Affect Study Enrollment.
49. CNS Drug Development: Lessons Learned Part 2. Symptoms, Not Syndromes as Targets Consistent with the NIMH Research Domain Approach.
50. CNS drug development: lessons from the development of ondansetron, aprepitant, ramelteon, varenicline, lorcaserin, and suvorexant. Part I.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.